
-
Protagenic Therapeutics NasdaqCM:PTIX Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. The company's lead compound comprises PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. Protagenic Therapeutics, Inc. is headquartered in New York, New York.
Location: 149 Fifth Avenue, New York, NY, 10010, United States | Website: https://www.protagenic.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
911.6K
Cash
873K
Avg Qtr Burn
-906.3K
Short % of Float
3.51%
Insider Ownership
16.53%
Institutional Own.
7.01%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
PT00114 Details Addiction, Post-traumatic stress disorder, Treatment Resistant Depression, Social Anxiety Disorder | Phase 1/2 Data readout |